期刊文献+

Differential Proteomics in Malignant and Normal Liver Cell Lines

Differential Proteomics in Malignant and Normal Liver Cell Lines
暂未订购
导出
摘要 Objective: To detect differential protein expression in malignant and normal liver cell lines in vitro using the SELDI ProteinChip platform, for investigating the pathogenesis of liver cancer. Methods: Two cell lines, human normal liver cell line L02 and hepatoma cell line SMMC-7721 were cultured routinely, harvested in good condition and lysed. After quantification, the supernatant of the lysate was tested by IMAC3 (Immobilized Mental Affinity Capture) and WCX2 (Weak Cation Exchange) chips on the SELDI-TOF-MS ProteinChip reader. Results: Protein expression differed between the malignant and normal liver cell lines. A total of 20 differentially expressed proteins were found, among which, 7 were captured by the IMAC3 chip and 14 by the WCX2 chip. Peaks at 5,419, 7,979 and 11,265 Da were higher and at 8,103, 8,492, 10,160 and 11,304 Da lower in SMMC-7721 cells by the IMAC3 chip; peaks at 7,517, 7,945 and 7,979 Da were higher and at 5,061, 5,551, 5,818, 7,439, 9,401,10,100, 10,312, 11,621, 11,662, 11,830 and 12,772 Da lower in SMMC-7721 cells by the WCX2 chip. Interestingly, both chips captured the 7,979 Da peak. In addition, the 11,081 Da peak corresponded precisely with the molecular mass of the calcium binding protein S100A10, which may participate in the formation of liver cancer in association with p36. Conclusion: Detecting differential protein expression in malignant and normal liver cell lines using the SELDI ProteinChip platform was simple, sensitive and repeatable. The results we obtained can serve as a basis for investigating the pathogenesis of liver cancer and aid the discovery of new therapeutic targets. Objective: To detect differential protein expression in malignant and normal liver cell lines in vitro using the SELDI ProteinChip platform, for investigating the pathogenesis of liver cancer. Methods: Two cell lines, human normal liver cell line L02 and hepatoma cell line SMMC-7721 were cultured routinely, harvested in good condition and lysed. After quantification, the supernatant of the lysate was tested by IMAC3 (Immobilized Mental Affinity Capture) and WCX2 (Weak Cation Exchange) chips on the SELDI-TOF-MS ProteinChip reader. Results: Protein expression differed between the malignant and normal liver cell lines. A total of 20 differentially expressed proteins were found, among which, 7 were captured by the IMAC3 chip and 14 by the WCX2 chip. Peaks at 5,419, 7,979 and 11,265 Da were higher and at 8,103, 8,492, 10,160 and 11,304 Da lower in SMMC-7721 cells by the IMAC3 chip; peaks at 7,517, 7,945 and 7,979 Da were higher and at 5,061, 5,551, 5,818, 7,439, 9,401,10,100, 10,312, 11,621, 11,662, 11,830 and 12,772 Da lower in SMMC-7721 cells by the WCX2 chip. Interestingly, both chips captured the 7,979 Da peak. In addition, the 11,081 Da peak corresponded precisely with the molecular mass of the calcium binding protein S100A10, which may participate in the formation of liver cancer in association with p36. Conclusion: Detecting differential protein expression in malignant and normal liver cell lines using the SELDI ProteinChip platform was simple, sensitive and repeatable. The results we obtained can serve as a basis for investigating the pathogenesis of liver cancer and aid the discovery of new therapeutic targets.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2007年第2期94-99,共6页 中国癌症研究(英文版)
基金 the grant from the National Natural Science Foundation of China(No.30471527, No. 30540075) Mt. Tai Scholar Construction Engineering Foundation
关键词 SELDI ProteinChip Liver cancer cell line SMMC-7721 Normal liver cell line L02 Protein expression SELDI ProteinChip Liver cancer cell line SMMC-7721 Normal liver cell line L02 Protein expression
  • 相关文献

参考文献17

  • 1Pandey A,Mann M.Proteomics to study genes and genomes[J].Nature 2000; 405:837-46.
  • 2Jungblut PR,Zimny-Arndt U,Zeindl-Eberhart E,et al.Proteomics in human diseases:cancer,heart and infectious diseases[J].Electrophoresis 1999; 20:2100-10.
  • 3Peng J,Gygi SP.Proteomics:The move to mixtures[J].J Mass Spectrom 2001; 36:1083-91.
  • 4Persidsky Y,Gendelman HE.Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection[J].J Leukoc Biol 2003; 74:691-701.
  • 5Vlahou A,Schellhammer PF,Mendrinos S,et al.Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine[J].Am J Pathol 2001; 158:1491-502.
  • 6Petricoin EF,Ardekani AM,Hitt BA,et al.Use of proteomic patterns in serum to Identify ovarian cancer[J].Lancet 2002; 359:572-7.
  • 7Petricoin EF 3rd,Ornstein DK,Paweletz CP,et al.Serum proteomic patterns for detection of prostate cancer[J].J Natl Cancer Inst 2002; 94:1576-8.
  • 8Li J,Zhang Z,Rosenzweig J,et al.Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer[J].Clin Chem 2002; 48:1296-304.
  • 9Poon TC,Yip TT,Chan AT.Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes[J].Clin Chem 2003; 49:752-60.
  • 10Shiwa M,Nishimura Y,Wakatabe R,et al.Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform[J].Biochem Biophys Res Commun 2003; 309:18-25.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部